Orgenesis acquired MaSTherCell, an emerging pioneer in the industrialization of cell-based therapeutics based in Gosselies, Belgium, as part of the American company’s plan to increase its global presence and capabilities.
The American and the Belgian companies have already been working jointly since last year to scale manufacturing of Orgenesis’ insulin-producing liver cells to fight diabetes. Now, Orgenesis has entered into a share exchange agreement with MaSTherCell and Cell Therapy Holding (collectively “MaSTherCell”) and each of the shareholders of the MaSTherCell.
Vered Caplan, chairperson and CEO of Orgenesis, said: “The acquisition of MaSTherCell creates incremental value for both companies in business-critical ways. First, it allows us to accelerate the transition of our lead product, Autologous Insulin Producing Cells (AIPCs) being developed as a therapeutic for type 1 diabetes, from pre-clinical testing into clinical trials. Second, the acquisition will also allow us to diversify our business model and future product offering.“
Orgenesis is an innovator in the technology of “cellular trans-differentiation”. This process involves re-programming one adult cell type to function like an adult cell of a different type.